Nautilus Biotechnology, Inc.

Good morning, and thank you for standing by. Welcome to the Nautilus Biotechnology's second quarter 2021 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. I would now like to hand the conference over to your speaker today, Carrie Mendeville with Investor Relations. Please go ahead.

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30th, 2021. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Harad Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 10, 2021. With that, I'd like to turn the call over to Sigal.

Thanks, Carrie, and good morning to all of you. I'm excited to welcome you to Nautilus' first earnings call as a public company. This morning, we'll review our results for the second quarter of fiscal year 21 and provide some color and context around the significant opportunity we see in front of us. Before I get started, I'd like to take a moment to express my sincere thanks to our remarkable team for their hard work and focused execution. Our continued progress as a company is a reflection of the resiliency and quality of the individuals that make up Team Nautilus in the Bay Area and Seattle. I'm very proud to work with each of them. I'd also like to thank our longstanding investors for their continued support and provide a special welcome to our new investors. We look forward to continuing to develop meaningful, long-term relationships with you as we grow the company and pursue our ambitious goals. Speaking of those goals, and to put it as clearly as I can, we believe that Nautilus has nothing less than the potential to revolutionize biomedical research by unlocking the potential of the proteome. The world needs a dramatic acceleration in drug development, an acceleration that we believe will be key to ushering in a new era of precision and personalized medicine. We believe a bold scientific leap is required to overcome the current limitations and to radically reinvent proteomics, something we view as one of the last and most significant untapped opportunities in biological science today. Our vision at Nautilus is to bring to market a complete end-to-end massive scale protein analysis platform comprised of instrumentation, reagents, and software, which takes sample in, and returns unique biological data and insight out. To accomplish this, we've designed a single molecule analysis platform of extreme sensitivity, scale, and ease of use. Leveraging a unique architecture combined with advanced machine learning and algorithms, we believe our platform has the potential to identify substantially all proteins in sample from almost any organism. What I'm describing is not an incremental or evolutionary improvement over existing methods. It represents the bold scientific leap I referred to earlier, a complete reimagining that we believe has the potential to unlock the promise of the global proteomics market. Estimates indicate that currently the proteomics market is approximately $25 billion and growing at a 12% CAGR. While this market opportunity is an immediate and exciting area of focus for us, we're looking over the horizon at the potential long-term transformation of healthcare that could be fueled by proteomics. Much as democratizing access to the genome was a catalyst for the development of a broad, vibrant, and healthy genomics ecosystem, we believe that Nautilus' innovation has the potential to spark a renaissance in proteomics that could unlock high-value applications in precision and personalized medicine, in drug discovery, and in diagnostics. With that, I'll now turn the call over to Parag.